Mode
Text Size
Log in / Sign up
Phase 2 N=134 Randomized Quadruple-blind Treatment

PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery

Breast Cancer · Breast Cancer Female · Cancer of Breast

Enrolled (actual)
134
Serious AEs
0.0%
Results posted
Mar 2022
Primary outcome: Primary: Worst Pain as Measured by the Brief Pain Inventory (BPI) at 1 Year — 0; 0 score on a scale — p=0.68

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Bupivacaine (Drug); Gabapentin (Drug); Celecoxib (Drug); Acetaminophen (Drug); Midazolam (Drug); Fentanyl (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
Female
Sponsor
Washington University School of Medicine
Primary completion
Feb 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
Worst Pain as Measured by the Brief Pain Inventory (BPI) at 1 Year
0; 0 0.68
PRIMARY
Average Pain as Measured by the Brief Pain Inventory (BPI) at 1 Year
0; 0 0.67
PRIMARY
Interference as Measured by the Brief Pain Inventory (BPI) at 1 Year
0; 0 0.53
SECONDARY
Change in Quality of Life as Measured by the Veterans RAND12 Questionnaire Physical Health Summary Measure
-3.1; -0.8 0.44
SECONDARY
Change in Quality of Life as Measured by the Veterans RAND12 Questionnaire Mental Health Summary Measure
0; 1.9 0.88

Summary

In this double blinded randomized placebo-controlled trial, 160 subjects scheduled for breast surgery involving the axilla will be administered a multimodal pain regimen including acetaminophen, dexamethasone, celecoxib, and gabapentin. 80 subjects will also receive a Pectoral Nerve blocks I and II (PECS I and II block) preoperatively.

Eligibility Criteria

Inclusion Criteria

  • Scheduled to undergo elective breast cancer surgeries at Barnes-Jewish Hospital:
  • unilateral axillary dissection
  • unilateral modified radical mastectomy
  • mastectomy with same day unilateral reconstruction
  • unilateral sentinel lymph node biopsy (SLNB)
  • partial mastectomy with unilateral SLNB
  • simple mastectomy with unilateral SLNB
  • At least 18 years of age.
  • Able to understand and willing to sign an Institutional Review Board (IRB)-approved written informed consent document.
  • Enrollment in the SATISFY-SOS study (WUSTL IRB# 201203088, NCT02032030).

Exclusion Criteria

  • Planned for bilateral axillary or bilateral reconstruction surgery.
  • Previous surgery on the surgical breast and/or axilla with the exception of partial mastectomy or sentinel lymph node biopsy
  • Pre-existing pain in the axilla affecting the ability to use extremity for activities of daily living or requiring medication for treatment.
  • Current or past medical history of liver disease or cirrhosis with an elevated INR >1.4 or currently elevated transaminase levels.
  • Known contraindications to peripheral nerve block placement.
  • Pregnant or breastfeeding.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition
  • Planned additional surgery to the surgical breast or axilla in the next year (exception would be minor surgery to breast but not axilla such as simple tissue expander replacement or lumpectomy)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03084536). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search